“a nonsignificant trend”

Across all TCGA breast cancer cases, enrichment of the murine AGED signature showed a nonsignificant trend toward shorter PFS (HR = 1.3, 95% CI = 0.9–1.8; p = 0.17; n = 1109) (Fig. 7C ), that became significantly associated with worse PFS among women age ≥65 years at breast cancer diagnosis (HR = 1.9, 95% CI = 1.0–3.6; p = 0.036; n = 323) (Fig. 7D ).

Regarding predictors of AVF outcomes in our study, while DM showed a nonsignificant trend toward higher AVF flow rate (β = 306; p = 0.17) we observed a significant inverse association between age and AVF flow rate (−14 mL/min/year).

Although a nonsignificant trend toward longer survival (9.6 versus 8.3 months HR 0.89, P = 0.17) was reported, the primary end point of improved PFS in the cetuximab arm was not met (4.4 versus 4.2 months, P = 0.2).

In fact, the first trial, the CHAMPION PLATFORM trial, 9 comparing cangrelor vs clopidogrel in more than 5,000 patients undergoing percutaneous coronary intervention, observed a nonsignificant trend of benefit with cangrelor (HR: 0.87; P = 0.17).

There was a nonsignificant trend toward less grade 3 or 4 neutropenia in the 48 h and 72 h fasting cohorts compared to the 24 h fasting cohort ( p = 0.17).

There was a nonsignificant trend toward better outcomes after alteplase versus control among patients with obstructed (OR, 1.86; 95% CI, 0.76–4.53; P =0.171) versus patent (OR, 0.72; 95% CI, 0.42–1.25; P =0.241) arteries on the IST-3 angiography score, P =0.075 for interaction (Figures 1 and 2 ).

There was a nonsignificant trend toward an improved OS (16.6 months vs 13.3 months, HR 0.85, 95% CI 0.66–1.08, P <0.174); however, the true effect of bevacizumab on OS is obscured and likely diluted by a 40% crossover to bevacizumab monotherapy among patients in the chemotherapy arm at the time of disease progression.

Similarly, there was a nonsignificant trend towards lower volume loss in the study group with a distal adjacent tooth across all ROIs ( p = 0.174). 4.

The combined clinical data of cohort-1 ( 47 ) and cohort-2 ( Figure 6B ) suggest that DEX prophylaxis may mildly mitigate acute high altitude PH (HAPH), a type of hypoxic PH, as the DEX-p group at HA had a nonsignificant trend toward lower RVSP (post hoc P values when accounting for multiple comparisons: P = 0.175).

Median PFS was 18.6 months (95% CI: 14.1–29.5) in the CRT+ICIs group versus 12.1 months (95% CI: 10.1–16.4) in the CRT group, with a nonsignificant trend toward improvement (p = 0.176, Figure 2D ).

Although this was a nonsignificant trend, the rate of VGI-related deaths was twice as high in patients with inadequate antimicrobial therapy (21.1% and 10.0%, P = .176).

Single lateral locking plate fixation showed a nonsignificant trend toward higher FRI odds (OR 2.76, 95% CI, 0.63 to 12.05, P = 0.177), whereas IMN (OR 1.65, 95% CI, 0.33 to 8.22, P = 0.539) and dual implants (OR 0.23, 95% CI, 0.02 to 2.57, P = 0.234) showed no significant association (Table 6 ).

There was a nonsignificant trend for decline in stage 0 versus stage 1 for FCSRT96 performance ( P = .178); however, stage 1 participants performed similarly to stage 0 participants for MMSE, LMDR, and DSC. 4 Discussion Our results suggest that a standard semantic memory measure (i.e., CAT to animals, fruits, and vegetables) adds independent information about amyloid-related cognitive decline not currently captured in the PACC.

7 However, what has not been highlighted is that in tight (versus less-tight) control, there was also a nonsignificant trend of similar magnitude toward a decrease in preterm birth (153, 31.5% versus 175, 35.6%, respectively; adjusted OR, 0.85 [0.64–1.11]; P =0.18).

Outcomes following Randomization Within the intervention group, there was a nonsignificant trend toward reduced airway collisions at 8 weeks (pre and post difference in means, −25.44 collisions; P = 0.18).

There was a nonsignificant trend toward reduced overall 12‐month MACE (17.1% versus 10.5%, P =0.18) driven mainly by a reduced incidence of heart failure ( P =0.04).

This effect was predominantly derived from observational studies (IRR = 0.37, 95% CI 0.21-0.66; P < .01), while the RCT subgroup showed a nonsignificant trend (IRR = 0.63, 95% CI 0.32-1.24; P = .18) ( Figure 2A ).

Histologic subtype showed a nonsignificant trend toward worse outcomes (HR = 1.55, 95% CI = 0.81-2.96, p = 0.18), and high PD-L1 expression (CPS ≥10) exhibited a similar trend toward poorer survival (HR = 1.68, 95% CI = 0.90-3.14, p = 0.09), although these did not reach statistical significance after adjustment, likely attributed to the limited number of PR cases and small cohort size (Table 2 ). 3.3.

When considering two groups of patients, those with detectable ctDNA and those with undetectable ctDNA, there was a nonsignificant trend toward inferior PFS and overall survival (OS) in those patients with the former (Log rank test, P = 0.18, Fig. 2B ; Log rank test, P = 0.22, Fig.

NR4A2 ( P = 0.002) and NR4A3 ( P = 0.035) were significantly down‐regulated in the dcSSc patient group (Figure 3B ), and NR4A1 showed a nonsignificant trend ( P = 0.18) for down‐regulation (Figure 3B ).

If anything, there was a nonsignificant trend demonstrating that those on MTX had greater improvement of FMD following BH 4 in comparison to those not on MTX (+4.6±5.0% versus +2.49±3.40%; P =0.18,).

This indicates a nonsignificant trend toward benefit with bempedoic acid (odds ratio [OR] 0.77, 95% confidence interval [CI] 0.52-1.13; P = 0.18).

There was a nonsignificant trend toward improved median OS in patients treated with HCQ with SMAD4 loss (34.43 months vs. 27.27 months, p = 0.18).

After adjustment for covariates, richness was reduced with surgery ( P = .007), and there was a nonsignificant trend for reduced Shannon index ( P = .18).

Figure 1 presents the distribution of grip strength z-score by CKD stages and shows a nonsignificant trend toward a lower grip strength in patients with decreased eGFR (CKD stage 2–4) compared with patients with preserved eGFR (stage 1; P = 0.18).